Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$203.66 USD
+2.83 (1.41%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $203.79 +0.13 (0.06%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
KRYS 203.66 +2.83(1.41%)
Will KRYS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KRYS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KRYS
Krystal Biotech (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
KRYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
Replimune (REPL) Gains on Positive Data From Melanoma Study
Other News for KRYS
Krystal Biotech participates in a conference call with Cantor Fitzgerald
Krystal Biotech participates in a conference call with Cantor Fitzgerald
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
TimesSquare Capital U.S. Small/Mid Cap Growth Q1 2024 Commentary